Related Experiment Video
Updated: Jan 20, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
A case report: X-linked dystrophin gene mutation causing severe isolated dilated cardiomyopathy
Geoffrey Lester1,2, Giuseppe Femia1,2, Julian Ayer2,3
1Department of Cardiology, Royal Prince Alfred Hospital, Camperdown 2050, Sydney, New South Wales, Australia.
Insights
X-linked dilated cardiomyopathy (XLDCM) is a rare, progressive heart muscle disease caused by dystrophin gene mutations. Diagnosis in young males with idiopathic cardiomyopathy is crucial, as cardiac transplantation is the definitive treatment.
Area of Science:
- Cardiology
- Genetics
- Neurology
Background:
- X-linked dilated cardiomyopathy (XLDCM) is a severe heart condition resulting from dystrophin gene mutations.
- Unlike other muscular dystrophies, XLDCM may present without skeletal muscle weakness, affecting only the heart.
- This isolated myocardial involvement can lead to rapid progression and heart failure.
Purpose of the Study:
- To highlight the presentation and diagnosis of X-linked dilated cardiomyopathy in a young male.
- To emphasize the importance of considering XLDCM in cases of unexplained cardiomyopathy.
- To discuss current treatment strategies for XLDCM.
Main Methods:
- A case study of a 16-year-old male presenting with stroke-like symptoms and subsequent cardiogenic shock.
- Diagnostic tools included CT angiography, CT brain, transthoracic echocardiography, cardiac magnetic resonance (CMR) imaging, and genetic testing.
- Treatment involved endovascular clot retrieval, inotropic support, heart failure therapy, and ultimately, cardiac transplantation.
Main Results:
- The patient experienced an acute ischemic stroke followed by severe left ventricular cardiomyopathy and cardiogenic shock.
- Genetic testing confirmed an X-linked dystrophin gene mutation (c.31+G>T), despite normal skeletal muscle.
- Cardiac MRI revealed significant left ventricular dysfunction and myocardial scarring.
Conclusions:
- XLDCM is a rapidly progressing cardiomyopathy with absent dystrophin in cardiac muscle and normal skeletal muscle.
- Early diagnosis through advanced imaging (CMR) and genetic testing is vital, especially in young males with idiopathic cardiomyopathy.
- Cardiac transplantation offers the best outcome for patients with severe XLDCM.
Background:
X-linked dilated cardiomyopathy (XLDCM) is a rare but rapidly progressive cardiomyopathy caused by dystrophin gene mutation. Mutations are more often associated with Duchenne and Becker Muscular Dystrophy, which are characterized by skeletal muscle weakness or limb girdle dystrophy. However, patients with isolated XLDCM have normal skeletal muscle but complete dystrophin loss in cardiac muscle resulting in isolated myocardial involvement without overt signs of skeletal myopathy.
Case Summary:
A previously well 16-year-old boy developed sudden onset dense left-sided weakness and facial droop. Computed tomography (CT) angiography and CT brain showed an occluded right internal carotid artery extending to the right middle cerebral artery. He underwent successful endovascular clot retrieval but developed frank pulmonary oedema and cardiogenic shock requiring inotropic support and intubation. Transthoracic echocardiography demonstrated severe left ventricular (LV) cardiomyopathy and an apical thrombus. Subsequent cardiac magnetic resonance (CMR) imaging confirmed the LV parameters and diffuse late gadolinium enhancement. Despite absence of skeletal manifestations, subsequent genetic testing revealed an X-linked dystrophin gene mutation [c.31+G>T (IVS1G>T)]. He was commenced on empirical heart failure therapy and underwent successful cardiac transplantation.
Discussion:
X-linked dilated cardiomyopathy is a rare, rapidly progressing cardiomyopathy. Patients show normal skeletal muscle dystrophin but absent expression in cardiac muscle, resulting fibrosis, and atrophy. About 20% of affected young males have significantly reduced survival and thus the diagnosis must be considered in cases of idiopathic cardiomyopathy with CMR and genetic testing key to the diagnosis. Whilst evidence exists for empirical heart failure medications, cardiac transplantation remains the definitive treatment.
More Related Videos
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Mutation, Gene Flow, and Genetic Drift
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Reporter Genes
Mutations
Cardiomyopathy IV: Restrictive Cardiomyopathy

